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BACKGROUND: Transcription factors often play important roles in tumourigenesis. Members of the PEA3 subfamily of ETS-domain
transcription factors fulfil such a role and have been associated with tumour metastasis in several different cancers. Moreover, the
activity of the PEA3 subfamily transcription factors is potentiated by Ras-ERK pathway signalling, which is itself often deregulated in
tumour cells.
METHODS:Immunohistochemical patterns of PEA3 expression and active ERK signalling were analysed and mRNA expression levels of
PEA3, ER81, MMP-1 and MMP-7 were determined in gastric adenocarcinoma samples.
RESULTS: Here, we have studied the expression of the PEA3 subfamily members PEA3/ETV4 and ER81/ETV1 in gastric
adenocarcinomas. PEA3 is upregulated at the protein level in gastric adenocarcinomas and both PEA3/ETV4 and ER81/ETV1 are
upregulated at the mRNA level in gastric adenocarcinoma tissues. This increased expression correlates with the expression of a target
gene associated with metastasis, MMP-1. Enhanced ERK signalling is also more prevalent in late-stage gastric adenocarcinomas, and
the co-association of ERK signalling and PEA3 expression also occurs in late-stage gastric adenocarcinomas. Furthermore, the co-
association of ERK signalling and PEA3 expression correlates with decreased survival rates.
CONCLUSIONS: This study shows that members of the PEA3 subfamily of transcription factors are upregulated in gastric
adenocarcinomas and that the simultaneous upregulation of PEA3 expression and ERK pathway signalling is indicative of late-stage
disease and a poor survival prognosis.
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Gastric cancer is the second commonest cause of a cancer death
worldwide. In Western populations, the incidence has been
steadily declining over the past decades (Samalin and Ychou,
2007; Bosetti et al, 2008). This is thought to be a result of a
decreasing incidence of Helicobacter pylori by chlorination of
drinking water and policies for antibiotic eradication. Despite
this reduction, in England gastric cancer remains ranked as the
sixth commonest cause of a cancer death (Rachet et al, 2009).
This is largely attributable due to the late presentation of the
disease and this limits treatment options. Five-year survival is
excellent if diagnosed at an early stage and population screening
by upper gastrointestinal endoscopy has increased the rates of
early detection and subsequent prognosis in Japanese populations
(Nosho et al, 2005; Tan and Fielding, 2006). In Western
populations, the incidence of gastric cancer is much lower
and population screening is not economically viable. As a result,
gastric adenocarcinomas are usually diagnosed at an advanced
stage and typical 5-year survival is 15%. Cytotoxic chemotherapy
regimens are largely ineffective in halting the disease (Findlay et al,
1994; Mackay et al, 2001; Tebbutt et al, 2002). Even when surgery
is possible, neoadjuvant cytotoxic chemotherapy improves 5-year
survival rates modestly from 20 to 36% (Cunningham et al, 2006).
New treatments and targets for drug therapies are needed to
improve outcomes further.
PEA3/ETV4 is a member of the PEA3 subfamily of ETS-domain
transcription factors. This subfamily also includes ER81/ETV1 and
ERM/ETV5. The ETS domain determines DNA-binding specificity,
it is highly conserved in all three PEA3 family proteins and this
suggests that they regulate similar promoters (de Launoit et al,
1997). This has been shown to be the case with other ETS family
members, where both promoter-specific and redundant binding
modes are operative (Hollenhorst et al, 2007; Boros et al, 2009).
The PEA3 family is important in development, with particular
recent emphasis on the nervous system (de Launoit et al, 1997;
Oikawa and Yamada, 2003; Sharrocks, 2001, Vrieseling and
Arber, 2006). However, much interest has surrounded PEA3
proteins because of their association with cancer. The proteins are
generally expressed at low levels in normal adult tissues, however,
in cancer tissues, mRNA and protein expression is often much
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shigher. PEA3 is associated with a variety of cancers including
colon, breast, ovarian, prostate and oesophageal cancer (de
Launoit et al, 2000; Horiuchi et al, 2003; Cowden Dahl et al,
2007; Tomlins et al, 2007; Keld et al, 2010). ER81 has been
associated with prostate, oesophageal and gastrointestinal stromal
tumours (Cai et al, 2007; Chi et al, 2010; Keld et al, 2010).
Where present, tumours are generally more aggressive, advanced
and prognosis is worse. It has been established that PEA3 proteins
are normally under auto-inhibitory control (reviewed in
Sharrocks, 2001). For optimal transcriptional activity, PEA3
proteins require activation by post-translational modification
from mitogenic signalling pathways. ERK MAP kinase signalling
is important for PEA3 and ER81 activation through direct
phosphorylation and subsequent SUMOylation (reviewed in de
Launoit et al, 2006; Guo et al, 2007; Brown et al, 1998; Janknecht,
2003; Goel and Janknecht, 2004; Guo and Sharrocks, 2009).
Various co-factors such as b catenin, c-Jun, p300 and LPP enhance
the transcriptional activity of PEA3 in cell line models (Gum et al,
1996; Crawford et al, 2001; Janknecht, 2003; Liu et al, 2004; Guo
et al, 2006; Matsui et al, 2006). This indicates that additional
factors are needed for optimal activity. The poor prognosis
associated with tumours that express PEA3 proteins is thought to
be due to the activation of genes encoding matrix metalloproteases
(MMP-1, 2, 7, 9, 11, 13 and 14) (Habelhah et al, 1999; Horiuchi
et al, 2003; Cai et al, 2007; Cowden Dahl et al, 2007), cell cycle
regulators (Cyclin D3; Jiang et al, 2007) and the production of
growth factors receptors (HER-2; O’Hagan and Hassell, 1998) and
mediators of angiogenesis (COX2 and VEGF; Howe et al, 2001; Hua
et al, 2009; Liu et al, 2004).
In gastric adenocarcinoma cell line models, PEA3 increases
MMP-1 and MMP-7 expression and stimulates invasion in vitro
(Yamamoto et al, 2004). The ERK MAPK kinase pathway has been
shown to activate PEA3 and increase MMP-1 levels by incubating
gastric cancer cells with H. pylori (Wu et al, 2006). In a recent
study, HER-2 was shown to drive MMP-1 expression and
gastric cancer cell invasion (Bao et al, 2010), but the role of
PEA3 in this process was not investigated. Our understanding of
the PEA3 family and ERK MAPK signalling in gastric adenocar-
cinoma is limited. One previous study looked at PEA3 in this context
and demonstrated that PEA3 mRNA expression is associated with
poor prognosis and disease recurrence in gastric adenocarcinoma
in a Japanese population (Yamamoto et al, 2004). The other
subfamily members ER81 and ERM did not influence disease stage
or outcome. The role of MAPK signalling was not investigated in
this study. No previous studies have investigated PEA3 or ER81 in
a Western population of gastric adenocarcinomas. Only one study
has investigated the status of ERK MAP kinase signalling in gastric
adenocarcinomas. Here, a low occurrence was found but clinical
correlations were not made (Feng et al, 2008). A three-way
association to generate an ERK-PEA3-MMP axis has been
described in cell lines derived from ovarian, oesophageal and
gastric cancer (Wu et al, 2006; Cowden Dahl et al, 2007; Keld et al,
2010). Moreover, both PEA3 and MMP-1 were shown to be
upregulated in patient-derived early-stage gastric cancer samples
from a Japanese population (Wu et al, 2006). This upregulation
was potentiated in the presence of H. pylori infection, thereby
suggesting a role for H. pylori-induced ERK pathway activity in
driving their expression. Here, we revisited this issue and
examined more directly whether the ERK-PEA3-MMP axis is
operative in gastric adenocarcinoma tissue.
Primarily, we investigated the expression of the PEA3 subfamily
members PEA3 and ER81 in gastric adenocarcinomas. Second, we
investigated upstream pathways by measuring ERK MAP kinase
activity and downstream pathways by determining the levels of the
putative targets MMP-1 and MMP-7. We found that increased
expression of both PEA3 and ER81 are associated with gastric
adenocarcinomas. Furthermore, PEA3 and ER81 expression are
associated with elevated MMP-1 and MMP-7 expression. In
isolation, PEA3 expression was not associated with poor prognosis
or an advanced disease stage. In adenocarcinoma tissue, PEA3
expression in combination with elevated ERK MAP kinase
signalling is associated with an advanced disease stage and a
reduced survival compared with specimens with ERK MAP kinase
signalling without PEA3 or in specimens with PEA3 expression in
isolation. This study indicates that the knowledge of transcription
factor expression in combination with the activity of the upstream
signalling pathways may also be important for patient selection to
tailor therapy more effectively to improve treatment response.
MATERIALS AND METHODS
Tissue collection
Ethical approval was granted by Wrightington Wigan and Leigh
Ethics Committee, UK in 2004. Tissue was collected from 40
patients with gastric adenocarcinomas and 15 healthy controls,
and clinical characteristics recorded as described previously (Keld
et al, 2010).
RNA isolation and RT–PCR analysis
RNA was extracted, its’ integrity determined and subsequent real-
time RT–PCR performed for PEA3, ER81, MMP-1, MMP-7 and 18S
RNA as described previously (Keld et al, 2010). Data are presented
relative to 18S RNA levels in the same samples. For relative
comparison of mRNA levels from tissue specimens, data were
further normalised to the level of each gene in a stock standard
concentration of RNA isolated from OE33 (for MMP-1 and MMP-
7), SW480 (for PEA3) and Flo1 (for ER81) cells. This latter
normalisation enabled experiments performed at different times to
be compared as mRNA concentrations were calculated relative to
the same standard stock mRNA preparation. The cell lines were
cultured and lysed as described previously (Keld et al, 2010).
Immunohistochemistry
Tissue microarray blocks were constructed from surgical resection
tumour blocks and biopsies as described previously (Keld et al,
2010). Three arrays were constructed for each case and stained
with PEA3 (Santa Cruz Biotechnology, Santa Cruz, CA, USA; Sc
113) and phosphorylated ERK (P-ERK) antibodies (New England
Biolabs, Ipswich, MA, USA; #437S) at a 1:20 and 1:100 dilution,
respectively. A negative control slide was tested without the
primary antibody to detect any background staining or false-
positive results. Three cores for each specimen were constructed
and scored by two expert histopathologists blinded to the clinical
details. A positive score was determined by the presence of positive
staining in 5% of tumour cells. An intensity score of 1–4 was also
determined. Moderate to high expression (intensity score 3 and 4)
was judged to be present if staining was visible easily at  20
magnification. The highest score in the triplet of cores was
recorded. We took moderate to high expression as positive for
PEA3 protein expression and P-ERK occurrence.
Statistical analysis
The software package SPSS 15.0 was utilised to analyse data. The
t-test was used to compare means of continuous variables. Fisher’s
exact test was used to compare discrete variables. Kaplan–Meier
analysis using the Breslow Wilcoxan test was used to calculate
survival curves by univariate analysis. Significance was accepted to
be present with a P-value o0.05.
PEA3/ETV4 and gastric adenocarcinoma
R Keld et al
125
British Journal of Cancer (2011) 105(1), 124–130 & 2011 Cancer Research UK
M
o
l
e
c
u
l
a
r
D
i
a
g
n
o
s
t
i
c
sRESULTS
PEA3 and ER81 are associated with gastric
adenocarcinomas
We recently demonstrated that PEA3 family members are
associated with oesophageal adenocarcinomas (Keld et al, 2010)
and wanted to know whether they are also associated with gastric
adenocarcinoma. First, we performed immunohistochemistry to
assess the expression of PEA3 at the protein level using a TMA
constructed from 39 gastric adenocarcinoma and 15 non-cancer
tissue specimens. Samples were then scored according to PEA3
levels and were considered as positive if they had moderate–high
PEA3 protein levels (Figure 1A; bottom panels). Moderate to high
PEA3 protein expression was present in 49% of adenocarcinomas
compared with 10% in non-cancer tissue (P-value¼0.018)
(Figure 1B). However, we did not identify a relationship between
PEA3-expressing tumours with H. pylori infection, tumour
differentiation, disease stage or survival, most likely because of
the low numbers involved. Thus, PEA3 protein expression is
associated with gastric adenocarcinomas in a Western population,
which is consistent with similar findings in mRNA expression
levels (Wu et al, 2006) and protein levels in Japanese populations
(Yamamoto et al, 2004).
PEA3 and ER81 are associated with MMP-1 and MMP-7
expression
To further extend the immunohistochemistry results, the levels of
PEA3 and ER81 mRNA were analysed in a subset of the normal and
adenocarcinoma-derived samples from patients. Samples from
normal tissue exhibited low-level expression of these two
transcription factors but a large number of tumour-derived
samples exhibited elevated expression of PEA3 and/or ER81
(Figures 2A and B; summarised in Figure 2E). The overall median
and the distribution of PEA3 and ER81 expression was 11- and
12-fold higher, respectively, in gastric cancer tissue compared with
non-cancer tissue (P-values 0.080 and 0.045, respectively) (Figures
2F and G). Elevated PEA3 and ER81 mRNA expression was seen in
42 and 79%, respectively, of gastric adenocarcinomas, which was
more often than observed in normal tissue. In the case of ER81, the
elevated frequency in tumours reached statistical significance
(P-values 0.063 and 0.008, respectively).
PEA3 has previously been shown to regulate MMP-1 and MMP-7
expression in gastric cancer cell lines (Yamamoto et al, 2004; Wu
et al, 2006). In Japanese populations, PEA3 expression has been
associated with MMP-7 expression in gastric adenocarcinomas
(Yamamoto et al, 2004), and high average levels of PEA3 and
MMP-1 expression have also been observed (Wu et al, 2006). We
therefore tested whether that PEA3 might be involved in regulating
MMP-1 and MMP-7 expression in our population. Samples from
normal tissue contained very low levels of mRNAs encoding these
two MMPs (Figures 2C and D; summarised in Figure 2E). In
contrast, elevated levels of mRNAs encoding both MMPs were
observed in samples from gastric adenocarcinomas, which were
particularly marked for MMP-1, where increased expression was
observed in 64% of gastric cancers (Figures 2C and D; summarised
in Figure 2E). Importantly, in all cases, elevated levels of MMP-1
expression in adenocarcinomas were associated with elevated
levels of PEA3 and/or ER81 (Figure 2E). A similar association was
seen for elevated MMP-7 expression. These data are therefore
consistent with a role for PEA3 and/or ER81 in regulating MMP
expression, although overexpression of the transcription factors
alone appears insufficient for inducing MMP expression, as there
are cases where PEA3 and/or ER81 are expressed but either MMP-1
and/or MMP-7 are not overexpressed (Figure 2E). Because of the
small number of tumours that do not express elevated expression
of PEA3 and/or ER81, it is not possible to determine whether the
lack of MMP expression in these tumours is statistically
significant. Similarly, we do not have any tumour samples that
express MMP1 and/or MMP7 and lack PEA3 and/or ER81, which
further exacerbates the inability to determine statistical signifi-
cance of the observed associations. Nevertheless, our results show
a strong association between the expression of PEA3 and/or ER81
and downstream MMPs.
Thus, PEA3 and ER81 are often upregulated at the mRNA level
in gastric adenocarcinomas, which is consistent with the results of
TMA analysis demonstrating overexpression of PEA3 protein in
this cancer type. Further, correlations with MMP expression
suggest that PEA3 family members may play an important role in
controlling these important mediators of tumour metastasis in this
context.
ERK MAPK signalling in combination with PEA3
expression is a marker of poor prognosis
The influence of ERK MAP kinase signalling on gastric cancer is
poorly understood. As ERK MAP kinase signalling is an important
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Figure 1 PEA3 protein expression in gastric adenocarcinomas.
(A) Examples of typical TMA staining (brown stain) for PEA3 protein in
normal gastric epithelium and adenocarcinoma (top panels H&E, bottom
panels PEA3 staining) at  20 and  40 magnification. (B) Summary of
TMA data for moderate–high PEA3 protein expression (scored as intensity
3 or 4) in patient samples from normal and adenocarcinoma tissue classes.
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therefore tested whether ERK signalling was activated in gastric
adenocarcinoma samples and whether this signalling was asso-
ciated with PEA3 subfamily member expression and subsequent
disease progression. An antibody raised against the activated
P-ERK was used to stain TMAs derived from gastric adenocarci-
noma samples to test for active ERK signalling. Examples of the
nuclear staining patterns of P-ERK in different classes of tissue are
illustrated in Figure 3A. We tested the same 39 gastric cancer
specimens and 15 non-cancer tissue specimens that we examined
for PEA3 expression. Active ERK signalling was observed in both
non-cancer tissue and cancer tissue, 79% compared with 54%
(Figure 3B) reflecting ERK signalling as a normal physiological
event in this tissue. However, subgroup analysis performed on the
39 gastric cancer specimens demonstrated that there were clear
differences in the levels of ERK signalling among cancer samples
(Figures 3A and C). Specimens with active ERK MAP kinase
signalling were more frequently seen in tumours with metastases
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Figure 2 Correlative expression of PEA3 and ER81 with MMP-1 and MMP-7 in gastric tissue specimens. (A–D) mRNA levels of PEA3 (A), ER81 (B),
MMP-1 (C) and MMP-7 (D) relative to 18S mRNA in tissue specimens are presented. All samples were standardised to mRNAs isolated from SW480
(for PEA3), Flo1 (for ER81) or OE33 (for MMPs) cell lines. The average relative mRNA levels and standard deviations derived from at least two readings
from one sample are shown. The individual tissue specimens are numbered. The samples are grouped according to the gastric tissue sub-types of normal
gastric epithelium (N), adenomatous polyp (P), intestinal metaplasia (IM) and adenocarcinomas (T). The average mRNA levels of the normal samples is
shown in red and indicated by the horizontal dotted line. (E) Heat map summary of the relative mRNA levels of PEA3, ER81, MMP1 and MMP7 in the gastric
tissue samples. Samples are categorised as ‘normal’ (light grey dots), ‘metaplasia (dark grey dots) or from patients with oesophageal adenocarcinomas (black
dots). Expression was defined as mRNA levels more than one standard deviation above the mean for the normal samples for each gene. Basal levels are
anything below this value (turquoise rectangles). Expression was then divided into three categories relative to the mean; high expression was anything more
than 100-fold (red rectangles), medium was between 25–100-fold (orange rectangles) and low was up to 25 fold (yellow rectangles) over the mean.
Groups of samples showing increased expression of MMP-1 and either PEA3 or ER81 relative to basal levels are bracketed. (F and G) Box plots of PEA3 (F)
and ER81 (G) mRNA expression in oesophageal tissue taken from normal healthy controls and gastric adenocarcinoma patients. Median relative expression
levels of PEA3 and ER81 are indicated for each tissue type. The box plot represents the inter-quartile range and the median value is indicated by the
horizontal line. The y axes in (F) is split and the high outliers are labelled by case number.
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s(Figure 3C; P-value¼0.040) and median survival was significantly
worse, 10 months compared with 27 months in samples with lower
ERK MAP kinase signalling activity (P-value¼0.050)(data not shown).
Next, we investigated if active ERK MAP kinase signalling
influenced the clinical outcomes in relation to PEA3 expression. In
cultured gastric cancer cells, it has been shown that ERK MAP
kinase signalling enhances PEA3 and MMP-1 expression (Wu et al,
2006). In gastric adenocarcinoma tissue, we have identified an
association between PEA3/ER81 and MMP-1 expression. We
therefore postulated that ERK signalling might influence clinical
features of gastric adenocarcinoma patients in relation to PEA3
expression either directly via influencing MMP expression or
through some other mechanism. The expression of elevated levels
of PEA3 protein and P-ERK signal was therefore compared among
the 39 tumour samples (Figure 3D). Tumours with little PEA3
protein expression and low P-ERK levels were all of the T&N stage
class. Conversely, tumours with a dual combination of elevated
PEA3 protein and P-ERK levels were more likely to have distant
metastases (M stage) than be at the T&N stage. Indeed, this
association with M stage was much stronger with this dual
combination compared with tumours with low expression or
activation of one factor in isolation (Figure 3D; w
2 P-value¼0.038).
Furthermore, a similar pattern is observed in patient survival
where the Kapplan–Meier graph shows a clear relationship
between PEA3 levels, P-ERK levels and patient survival
(Figure 3E). Patient survival is worse in the presence of elevated
levels of either PEA3 protein or P-ERK and even worse when both
levels are elevated together. However, in comparison with the
double-negative population neither P-ERK alone (P-value¼0.072)
or PEA3 expression alone (P-value¼0.199) reached statistical
significance compared with the significant association seen
with patients double positive for P-ERK and PEA3 expres-
sion (P-value¼0.019). Conversely, in comparison with the
double-positive population neither alone (P-value¼0.345)
nor PEA3 expression alone (P-value¼0.053) reached statistical
significance. Thus, only the presence of elevated levels of both
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Figure 3 Correlative expression of PEA3 with high levels of ERK MAPK signalling in gastric adenocarcinoma specimens. (A) Examples of typical TMA
staining (brown stain) for phosphorylated active ERK (P-ERK) levels in normal gastric epithelium, negative adenocarcinoma and positive adenocarcinoma (top
panels H&E, bottom panels P-ERK staining) at  20 and  40 magnification. (B) Summary of TMA data for moderate–high P-ERK signalling in patient
samples from normal and adenocarcinoma tissue classes. Positive ERK MAP kinase signalling is defined as more than 5% tumour cells staining positive for
P-ERK at intensity 3–4 at  20 magnification. (C) Histograms correlating the percentage of patients with TNM stage and phospho-ERK (P-ERK) levels
(as defined in B). (D) Patients with a combination of higher than basal P-ERK levels and above basal PEA3 protein expression are correlated with metastatic
M-stage disease. Positive P-ERK signals and PEA3 protein presence are defined as in (B). Data are presented as the percentage of patients containing the
indicated combinations of P-ERK and PEA3 levels, which have T and N (white bars) or M-stage (black bars) tumours. (E) Patients with the indicated
combinations of basal level ( ), and above basal P-ERK levels and PEA3 protein expression (þ) are correlated with % survival. The numbers of cases with
each combination of markers are shown in brackets.
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sPEA3 and P-ERK provides a reliable indicator of worse patient
prognosis.
Together these results indicate that although the occurrence of
elevated P-ERK in tumours is associated with late-stage disease,
the combination of elevated P-ERK levels and PEA3 expression is
more strongly associated with advanced-stage metastatic disease
and shorter survival.
DISCUSSION
Members of the PEA3 subfamily are associated with a variety of
cancers including colon, breast, ovarian, prostate and oesophageal
cancer (de Launoit et al, 2000; Horiuchi et al, 2003; Cowden Dahl
et al, 2007; Tomlins et al, 2007; Chi et al, 2010; Keld et al, 2010).
Here, we have demonstrated that increased expression of PEA3
and ER81 is associated with gastric adenocarcinoma in a Western
population and this is consistent with previous studies on an Asian
population (Yamamoto et al, 2004). Moreover, we have shown a
relationship between PEA3 and ER81 expression with the
expression of MMP-1 and, to a lesser extent, MMP-7 in gastric
adenocarcinomas. This mirrors the findings in gastric cancer cell
lines and in gastric cancer biopsies derived from Japanese
populations where PEA3 and MMP-1 overexpression was also
observed (Wu et al, 2006) or where an association between PEA3
and MMP-7 expression was thought to be more important for
cancer cell invasion (Yamamoto et al, 2004). In addition, we have
presented data for PEA3 expression in all stages of gastric
adenocarcinoma in our population whereas these previous findings
were mainly focussed on early gastric cancer. Our data suggest that
both PEA3 and ER81 are related to MMP-1 and MMP-7 expression.
Although the RNA analysis is underpowered and larger studies are
needed, the findings indicate that an inter-play between PEA3 and
ER81 may exist in relation to expression of MMP-1. Other ETS
proteins including ETS1, GABPa and Elk-1 are known to bind and
regulate the same gene promoters (Hollenhorst et al, 2007; Boros
et al, 2009). It is plausible that this mechanism may also be
operative with PEA3 and ER81 in different gastric adenocarcinomas.
Importantly, our results indicate that PEA3 mRNA or protein
expression in isolation is insufficient to specify cancer progression,
as no relationship was demonstrated with disease stage or
prognosis. Mechanisms derived from cell lines inform us that
PEA3 needs activation for optimal promoter transactivation
activity. A model of PEA3 activation by H. Pylori through ERK
MAP kinase signalling has been suggested in gastric cancer cells
and a similar mechanism of ERK activation appears to be
necessary for PEA3 activity in oesophageal and ovarian cancer
cell lines (Wu et al, 2006; Cowden Dahl et al, 2007; Keld et al,
2010). More recently, studies in gastrointestinal stromal tumours
indicate that c-KIT-mediated upregulation of ERK signalling is a
pre-requisite for the stabilisation of ER81 at the protein level and
the subsequent promotion of tumourigenesis (Chi et al, 2010). Our
studies suggest that similar mechanisms might also operate in
gastric adenocarcinomas as tumours with combinations of high
PEA3 and P-ERK levels fare worse than those with low levels of one
or both of these molecular events. However, we do not see an
obvious correlation between P-ERK and levels of PEA3 protein
expression in cancer samples, but this would likely only be
revealed by more quantitative western analysis rather than the
more subjective TMA analysis. Our data suggest that an axis of
ERK-PEA3/ER81-MMP-1/7 exists in these tumours as observed in
oesophageal adenocarcinomas (Keld et al, 2010) but this is not
confirmed in the current study, which is limited by design and
patient number. However, the information from the current study
may be important in tailoring cancer therapy in the future. We
have shown that PEA3 upregulation in isolation does not predict
prognosis in any stage of gastric cancer but that simultaneous
upregulation of PEA3 expression and ERK pathway signalling is
indicative of late-stage disease. Our data suggest a role for
targeting cancer therapies to tumours not only with an active
signalling pathway but also ones with a highly expressed
transcription factors known to regulate key carcinogenic genes.
Indeed, there are clearly two distinct gastric cancer populations
with high and low levels of active ERK, but importantly, normal
gastric tissue samples have high levels of active ERK, implying that
downregulation of ERK signalling occurs during tumourigenesis
with subsequent re-activation at some point, which associates with
late-stage disease. Clinical drug trials that inhibit the ERK pathway
at the growth factor receptor level (e.g., EGFR) or at the signal
transducer protein level (e.g., MEK) have yielded limited results
(Rinehart et al, 2004; Rojo et al, 2006). The identification of
additional signal-dependant transcription factors that influence
prognosis may improve future outcomes.
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